Ernexa Therapeutics Inc. ERNAW
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
-147.24
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$14.1M | — | -$7.1M | $2.4M |
| 2024 | $582,000 | -$44.5M | $486,000 | -$16.2M | $1.7M |
| 2023 | $68,000 | -$21.7M | -$168,000 | -$20.4M | $2.2M |
| 2022 | $0 | -$24.6M | $0 | -$21.3M | $12.1M |
| 2021 | — | -$122.5M | — | -$23.6M | $25.5M |
| 2020 | $5.8M | -$26.5M | — | -$8.1M | $7.7M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Cherington Charles | 10% owner | 2026-02-10 | Buy | 4,000,000 | $0.50 |
| Gurrola Sandra M | Sr. VP of Finance | 2025-06-21 | Option exercise | 30 | — |
| Cherington Charles | 10% owner | 2025-06-09 | Buy | 21,241,163 | $0.10 |
| Cherington Charles | 10% owner | 2025-04-02 | Buy | 3,768,397 | $0.10 |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -147.24 (distress)
- Working capital / assets 0.003
- Retained earnings / assets -42.104
- EBIT / assets -1.597
- Equity / liabilities 0.699
Source: SEC EDGAR filings · CIK 0000748592 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.